30
Participants
Start Date
November 28, 2025
Primary Completion Date
July 30, 2027
Study Completion Date
July 30, 2027
Glecaprevir/pibrentasvir
100 mg glecaprevir and 40 mg pibrentasvir for a total daily dose of glecaprevir 300 mg/pibrentasvir 120 mg
Bronx-Lebanon Hospital Center, The Bronx
Jacobi Medical Center, The Bronx
SUNY Stony Brook, Stony Brook
Johns Hopkins University Baltimore, Baltimore
Univ. of Florida Jacksonville, Jacksonville
Lurie Children's Hospital of Chicago, Chicago
Baylor College of Medicine//Texas Children's Hospital, Houston
University of Colorado Denver, Aurora
USC LA, Los Angeles
David Geffen School of Medicine at UCLA, Los Angeles
Collaborators (1)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
National Institute of Mental Health (NIMH)
NIH
AbbVie
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH